O	0	4	Role	Role	NN	B-NP
O	5	7	of	of	IN	B-PP
O	8	16	thrombin	thrombin	NN	B-NP
O	17	19	in	in	IN	B-PP
O	20	32	angiogenesis	angiogenesis	NN	B-NP
O	33	36	and	and	CC	I-NP
B-Cancer	37	42	tumor	tumor	NN	I-NP
O	43	54	progression	progression	NN	I-NP
O	54	55	.	.	.	O

O	56	64	Clinical	Clinical	JJ	B-NP
O	64	65	,	,	,	I-NP
O	66	76	laboratory	laboratory	NN	I-NP
O	76	77	,	,	,	O
O	78	95	histopathological	histopathological	JJ	B-ADJP
O	95	96	,	,	,	O
O	97	100	and	and	CC	O
O	101	116	pharmacological	pharmacological	JJ	B-NP
O	117	125	evidence	evidence	NN	I-NP
O	126	133	support	support	VBP	B-VP
O	134	137	the	the	DT	B-NP
O	138	144	notion	notion	NN	I-NP
O	145	149	that	that	IN	B-SBAR
O	150	153	the	the	DT	B-NP
O	154	165	coagulation	coagulation	NN	I-NP
O	166	172	system	system	NN	I-NP
O	172	173	,	,	,	O
O	174	179	which	which	WDT	B-NP
O	180	182	is	be	VBZ	B-VP
O	183	192	activated	activate	VBN	I-VP
O	193	195	in	in	IN	B-PP
O	196	200	most	most	JJS	B-NP
B-Cancer	201	207	cancer	cancer	NN	I-NP
O	208	216	patients	patient	NNS	I-NP
O	216	217	,	,	,	O
O	218	223	plays	play	VBZ	B-VP
O	224	226	an	an	DT	B-NP
O	227	236	important	important	JJ	I-NP
O	237	241	role	role	NN	I-NP
O	242	244	in	in	IN	B-PP
B-Cancer	245	250	tumor	tumor	NN	B-NP
O	251	258	biology	biology	NN	I-NP
O	258	259	.	.	.	O

O	260	263	Our	Our	PRP$	B-NP
O	264	274	laboratory	laboratory	NN	I-NP
O	275	278	has	have	VBZ	B-VP
O	279	287	provided	provide	VBN	I-VP
O	288	296	evidence	evidence	NN	B-NP
O	297	301	that	that	IN	B-SBAR
O	302	310	thrombin	thrombin	NN	B-NP
O	311	320	activates	activate	VBZ	B-VP
O	321	333	angiogenesis	angiogenesis	NN	B-NP
O	333	334	,	,	,	O
O	335	336	a	a	DT	B-NP
O	337	344	process	process	NN	I-NP
O	345	350	which	which	WDT	B-NP
O	351	353	is	be	VBZ	B-VP
O	354	363	essential	essential	JJ	B-ADJP
O	364	366	in	in	IN	B-PP
B-Cancer	367	372	tumor	tumor	NN	B-NP
O	373	379	growth	growth	NN	I-NP
O	380	383	and	and	CC	I-NP
O	384	394	metastasis	metastasis	NN	I-NP
O	394	395	.	.	.	O

O	396	400	This	This	DT	B-NP
O	401	406	event	event	NN	I-NP
O	407	409	is	be	VBZ	B-VP
O	410	421	independent	independent	JJ	B-ADJP
O	422	424	of	of	IN	B-PP
O	425	431	fibrin	fibrin	NN	B-NP
O	432	441	formation	formation	NN	I-NP
O	441	442	.	.	.	O

O	443	445	At	At	IN	B-PP
O	446	449	the	the	DT	B-NP
B-Cell	450	458	cellular	cellular	JJ	I-NP
O	459	464	level	level	NN	I-NP
O	465	469	many	many	JJ	I-NP
O	470	477	actions	action	NNS	I-NP
O	478	480	of	of	IN	B-PP
O	481	489	thrombin	thrombin	NN	B-NP
O	490	493	can	can	MD	B-VP
O	494	504	contribute	contribute	VB	I-VP
O	505	507	to	to	TO	B-PP
O	508	518	activation	activation	NN	B-NP
O	519	521	of	of	IN	B-PP
O	522	534	angiogenesis	angiogenesis	NN	B-NP
O	534	535	:	:	:	O
O	536	537	(	(	(	B-LST
O	537	538	1	1	LS	I-LST
O	538	539	)	)	)	O
O	539	540	.	.	.	O

O	541	549	Thrombin	Thrombin	NN	B-NP
O	550	559	decreases	decrease	VBZ	B-VP
O	560	563	the	the	DT	B-NP
O	564	571	ability	ability	NN	I-NP
O	572	574	of	of	IN	B-PP
B-Cell	575	586	endothelial	endothelial	JJ	B-NP
I-Cell	587	592	cells	cell	NNS	I-NP
O	593	595	to	to	TO	B-VP
O	596	602	attach	attach	VB	I-VP
O	603	605	to	to	TO	B-PP
B-Cellular_component	606	614	basement	basement	NN	B-NP
I-Cellular_component	615	623	membrane	membrane	NN	I-NP
O	624	632	proteins	protein	NNS	I-NP
O	632	633	.	.	.	O

O	634	635	(	(	(	O
O	635	636	2	2	CD	B-NP
O	636	637	)	)	)	O
O	637	638	.	.	.	O

O	639	647	Thrombin	Thrombin	NN	B-NP
O	648	655	greatly	greatly	RB	B-VP
O	656	667	potentiates	potentiate	VBZ	I-VP
O	668	676	vascular	vascular	JJ	B-NP
O	677	688	endothelial	endothelial	JJ	I-NP
O	689	695	growth	growth	NN	I-NP
O	696	702	factor	factor	NN	I-NP
O	702	703	-	-	HYPH	O
O	704	705	(	(	(	O
O	705	709	VEGF	VEGF	NN	B-NP
O	709	710	-	-	SYM	B-ADJP
O	710	711	)	)	)	O
O	712	719	induced	induce	VBD	B-VP
B-Cell	720	731	endothelial	endothelial	JJ	B-NP
I-Cell	732	736	cell	cell	NN	I-NP
O	737	750	proliferation	proliferation	NN	I-NP
O	750	751	.	.	.	O

O	752	756	This	This	DT	B-NP
O	757	769	potentiation	potentiation	NN	I-NP
O	770	772	is	be	VBZ	B-VP
O	773	784	accompanied	accompany	VBN	I-VP
O	785	787	by	by	IN	B-PP
O	788	790	up	up	RB	B-ADVP
O	790	791	-	-	HYPH	O
O	791	801	regulation	regulation	NN	B-NP
O	802	804	of	of	IN	B-PP
O	805	808	the	the	DT	B-NP
O	809	819	expression	expression	NN	I-NP
O	820	822	of	of	IN	B-PP
O	823	827	VEGF	VEGF	NN	B-NP
O	828	837	receptors	receptor	NNS	I-NP
O	838	839	(	(	(	O
O	839	845	kinase	kinase	NN	B-NP
O	846	852	insert	insert	NN	I-NP
O	853	859	domain	domain	NN	I-NP
O	859	860	-	-	HYPH	O
O	860	870	containing	contain	VBG	B-VP
O	871	879	receptor	receptor	NN	B-NP
O	880	881	[	[	(	O
O	881	884	KDR	KDR	NN	B-NP
O	884	885	]	]	)	O
O	886	889	and	and	CC	O
O	890	893	fms	fm	NNS	B-NP
O	893	894	-	-	HYPH	B-NP
O	894	898	like	like	JJ	I-NP
O	899	907	tyrosine	tyrosine	NN	I-NP
O	908	914	kinase	kinase	NN	I-NP
O	915	916	[	[	(	O
O	916	919	Flt	Flt	NN	B-NP
O	919	920	-	-	HYPH	B-NP
O	920	921	1	1	CD	I-NP
O	921	922	]	]	)	O
O	922	923	)	)	)	O
O	923	924	.	.	.	O

O	925	926	(	(	(	O
O	926	927	3	3	CD	B-NP
O	927	928	)	)	)	O
O	928	929	.	.	.	O

O	930	938	Thrombin	Thrombin	NN	B-NP
O	939	948	increases	increase	VBZ	B-VP
O	949	952	the	the	DT	B-NP
O	953	957	mRNA	mRNA	NN	I-NP
O	958	961	and	and	CC	I-NP
O	962	969	protein	protein	NN	I-NP
O	970	976	levels	level	NNS	I-NP
O	977	979	of	of	IN	B-PP
O	980	985	alpha	alpha	NN	B-NP
O	986	987	(	(	(	O
O	987	988	v	v	NN	B-NP
O	988	989	)	)	)	O
O	989	993	beta	beta	NN	B-NP
O	994	995	(	(	(	O
O	995	996	3	3	CD	B-NP
O	996	997	)	)	)	O
O	998	1006	integrin	integrin	NN	B-NP
O	1007	1010	and	and	CC	O
O	1011	1017	serves	serve	VBZ	B-VP
O	1018	1020	as	as	IN	B-PP
O	1021	1022	a	a	DT	B-NP
O	1023	1029	ligand	ligand	NN	I-NP
O	1030	1032	to	to	TO	B-PP
O	1033	1037	this	this	DT	B-NP
O	1038	1046	receptor	receptor	NN	I-NP
O	1046	1047	.	.	.	O

O	1048	1059	Furthermore	Furthermore	RB	B-ADVP
O	1059	1060	,	,	,	O
O	1061	1069	thrombin	thrombin	NN	B-NP
O	1070	1079	increases	increase	VBZ	B-VP
O	1080	1083	the	the	DT	B-NP
O	1084	1093	secretion	secretion	NN	I-NP
O	1094	1096	of	of	IN	B-PP
O	1097	1101	VEGF	VEGF	NN	B-NP
O	1102	1105	and	and	CC	O
O	1106	1114	enhances	enhance	VBZ	B-VP
O	1115	1118	the	the	DT	B-NP
O	1119	1129	expression	expression	NN	B-NP
O	1130	1133	and	and	CC	O
O	1134	1141	protein	protein	NN	B-NP
O	1142	1151	synthesis	synthesis	NN	I-NP
O	1152	1154	of	of	IN	B-PP
O	1155	1161	matrix	matrix	NN	B-NP
O	1162	1177	metalloprotease	metalloprotease	NN	I-NP
O	1177	1178	-	-	HYPH	B-NP
O	1178	1179	9	9	CD	I-NP
O	1180	1183	and	and	CC	O
O	1184	1189	alpha	alpha	SYM	B-NP
O	1190	1191	(	(	(	O
O	1191	1192	v	v	NN	B-NP
O	1192	1193	)	)	)	O
O	1193	1197	beta	beta	NN	B-NP
O	1198	1199	(	(	(	O
O	1199	1200	3	3	CD	B-NP
O	1200	1201	)	)	)	O
O	1202	1210	integrin	integrin	NN	B-NP
O	1211	1213	in	in	IN	B-PP
O	1214	1219	human	human	JJ	B-NP
B-Cell	1220	1228	prostate	prostate	NN	I-NP
I-Cell	1229	1235	cancer	cancer	NN	I-NP
I-Cell	1236	1238	PC	PC	NN	I-NP
I-Cell	1238	1239	-	-	HYPH	B-NP
I-Cell	1239	1240	3	3	CD	I-NP
I-Cell	1241	1246	cells	cell	NNS	I-NP
O	1246	1247	.	.	.	O

O	1248	1253	These	These	DT	B-NP
O	1254	1261	results	result	NNS	I-NP
O	1262	1267	could	could	MD	B-VP
O	1268	1275	explain	explain	VB	I-VP
O	1276	1279	the	the	DT	B-NP
O	1280	1290	angiogenic	angiogenic	JJ	I-NP
O	1291	1294	and	and	CC	I-NP
B-Cancer	1295	1300	tumor	tumor	NN	I-NP
O	1300	1301	-	-	HYPH	O
O	1301	1310	promoting	promote	VBG	B-VP
O	1311	1317	effect	effect	NN	B-NP
O	1318	1320	of	of	IN	B-PP
O	1321	1329	thrombin	thrombin	NN	B-NP
O	1330	1333	and	and	CC	O
O	1334	1341	provide	provide	VBP	B-VP
O	1342	1345	the	the	DT	B-NP
O	1346	1351	basis	basis	NN	I-NP
O	1352	1355	for	for	IN	B-PP
O	1356	1367	development	development	NN	B-NP
O	1368	1370	of	of	IN	B-PP
O	1371	1379	thrombin	thrombin	NN	B-NP
O	1380	1388	receptor	receptor	NN	I-NP
O	1389	1397	mimetics	mimetic	NNS	I-NP
O	1398	1400	or	or	CC	I-NP
O	1401	1412	antagonists	antagonist	NNS	I-NP
O	1413	1416	for	for	IN	B-PP
O	1417	1428	therapeutic	therapeutic	JJ	B-NP
O	1429	1440	application	application	NN	I-NP
O	1440	1441	.	.	.	O

